Clinical Trial Update: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the Shingrix vaccine in patients with moderate to severe ulcerative colitis on tofacitinib was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)
• Tofacitinib (tofacitinib)

Snippet

Sponsor: Boston Medical Center | Conditions: Inflammatory Bowel Diseases | Phase 4 | Status: TERMINATED | Results posted: 2025-02-21